Document Detail

How can we prevent and treat cardiogenic shock in patients who present to non-tertiary hospitals with myocardial infarction? A systematic review.
MedLine Citation:
PMID:  19374618     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate current evidence in support of therapies for preventing and treating cardiogenic shock (CS) after acute myocardial infarction that can be initiated in hospitals without invasive cardiac facilities. STUDY DESIGN: Systematic review. DATA SOURCES: MEDLINE and PubMed were searched from January 1985 to May 2008 using the MeSH terms "myocardial infarction", "thrombolytic therapy", "shock, cardiogenic", "angioplasty, transluminal, percutaneous coronary", "intra-aortic balloon pumping" and "platelet aggregation inhibitors". Additional keyword and reference list searches were performed. Articles in English relating to adults were included. STUDY SELECTION: Meta-analyses and comparative studies were included if they reported mortality or prevention of CS as an endpoint. In total, 35 articles were analysed (four meta-analyses, eight randomised controlled trials and 23 cohort studies). DATA EXTRACTION: Studies were summarised by the first author and the level of evidence graded. Each study was checked by the second author and consensus was reached about inclusion and levels of evidence. DATA SYNTHESIS: In the management and prevention of CS, the following are supported by high-level evidence: prehospital thrombolysis, transfer for emergency revascularisation (patients aged < 75 years) and thrombolysis for older patients (patients aged > or = 75 years). In established CS, evidence supporting inhospital thrombolysis and intra-aortic balloon pump use in patients aged < 75 years and emergency revascularisation in older patients is limited to subgroup analyses and observational studies. CONCLUSIONS: In regional centres, prevention of CS is achieved with early fibrinolysis, preferably before hospital arrival. Patients of all ages should be considered for thrombolysis, early transfer for coronary revascularisation, and intra-aortic balloon pump insertion unless contraindicated. Glycoprotein inhibitors have no role in the management of CS in non-tertiary hospitals.
Enda O'Connor; John F Fraser
Related Documents :
10505908 - Using clinical indicators in emergency medicine: documenting performance improvements t...
17463318 - Size matters: hemorrhage volume as an objective measure to define significant intracran...
19054698 - When is thrombolysis for acute lower limb ischemia worthwhile?
14752128 - Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in ac...
10956298 - Coronary artery compliance and adaptive vessel remodelling in patients with stable and ...
25422328 - The mystery of recurrent idiopathic cerebrovascular and coronary arterial thrombosis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  The Medical journal of Australia     Volume:  190     ISSN:  0025-729X     ISO Abbreviation:  Med. J. Aust.     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-04-20     Completed Date:  2009-07-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0400714     Medline TA:  Med J Aust     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  440-5     Citation Subset:  IM    
Prince Charles Hospital, Brisbane, QLD.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Emergency Medical Services / organization & administration
Intra-Aortic Balloon Pumping
Myocardial Infarction / complications,  diagnosis,  therapy*
Myocardial Revascularization
Shock, Cardiogenic / diagnosis,  etiology,  therapy*
Thrombolytic Therapy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Alcohol taxation policy in Australia: public health imperatives for action.
Next Document:  Genesis of medical thromboprophylaxis guidelines in Australia: a need for transparency and standardi...